drug

ABT-126

MeSH C000618299
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by AbbVie
5 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

5
Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)
NCT01834638Phase 2Terminated
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
NCT01655680Phase 2Completed
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
NCT01678755Phase 2Completed
Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia
NCT01095562Phase 2Completed
Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia
NCT01043458Phase 1Completed

KOLs & investigators

1
George Haig, PharmD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
AbbVie
company
trial
Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)
PHASE2
trial
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
PHASE2
trial
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
PHASE2
trial
Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia
PHASE2
trial
Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia
PHASE1
trial
indication
Cognitive Deficits in Schizophrenia
indication
Schizophrenia
indication
Schizophrenia
indication
KOL
George Haig, PharmD
KOL score —
person